BioLineRx Ltd. (BLRX)

BioLineRx Ltd. (BLRX) Healthcare & Pipeline Overview

BioLineRx Ltd. is an Israeli clinical-stage biopharmaceutical company focused on oncology, developing a pipeline of therapeutic candidates including Motixafortide for stem cell mobilization and pancreatic cancer, AGI-134 for solid tumors, and BL-5010 for skin lesions. The company leverages strategic collaborations to advance its drug development efforts.

What Is the Investment Thesis for BLRX?

BioLineRx Ltd. presents an investment thesis centered on its advanced clinical pipeline and strategic collaborations within the high-growth oncology and biotechnology sectors. The company's lead candidate, Motixafortide, having completed Phase 3 clinical trials for autologous stem cell mobilization, represents a significant value driver with potential for regulatory submission and commercialization. Furthermore, Motixafortide's ongoing Phase 2 development for metastatic pancreatic adenocarcinoma, a disease with substantial unmet medical need, offers considerable upside. The immuno-oncology agent AGI-134, currently in Phase 1/2a for solid tumors, positions BioLineRx in a rapidly expanding therapeutic area. The licensing agreement with Perrigo for BL-5010 provides a potential pathway to near-term revenue generation from a non-oncology asset. Strategic partnerships with industry leaders like MSD and MD Anderson Cancer Center validate the potential of BioLineRx's assets and provide access to additional resources and expertise. While the company operates with a negative profit margin of -633.8% and a market capitalization of $14.01M, typical for a clinical-stage biopharmaceutical firm, its diverse pipeline and collaborative approach aim to mitigate the inherent risks of drug development and unlock future value.

Based on FMP financials and quantitative analysis

BLRX Key Highlights

• Market Capitalization: $0.01 billion, indicating a micro-cap valuation typical for a clinical-stage biopharmaceutical company focused on research and development.
• Profit Margin: -633.8%, reflecting substantial ongoing R&D expenditures and the absence of significant commercialized product revenue, which is common for companies in the drug development phase.
• Gross Margin: 74.7%, a metric that, while high, should be contextualized within a clinical-stage company's minimal or non-existent product revenue, potentially reflecting specific revenue streams or early-stage operational efficiency.
• Beta: 0.59, suggesting lower volatility relative to the broader market, which is an interesting characteristic for a biotechnology company often perceived as high-risk.
• Employee Count: 28 employees, indicating a lean operational structure that manages multiple clinical programs and strategic collaborations efficiently.

Who Are BLRX's Competitors?

BLRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BLRX's Key Strengths?

• Advanced clinical pipeline with Motixafortide having completed Phase 3 trials for autologous stem cell mobilization.
• Strategic collaborations with major industry players like MSD and MD Anderson Cancer Center.
• Diversified pipeline addressing multiple indications, including oncology and acute respiratory distress syndrome.
• Potential near-term revenue stream from BL-5010 through a licensing agreement with Perrigo.

What Are BLRX's Weaknesses?

• Negative profit margin of -633.8%, indicating significant cash burn typical of a clinical-stage company.
• Reliance on successful clinical trial outcomes for pipeline assets, which are inherently high-risk.
• Small market capitalization ($0.01B) and employee base (28), potentially limiting resources compared to larger competitors.
• No currently commercialized products generating substantial revenue, leading to funding dependency.

What Could Drive BLRX Stock Higher?

• Potential regulatory submission for Motixafortide in autologous stem cell mobilization following the successful completion of its Phase 3 clinical trials.
• Advancement of Motixafortide's Phase 2 clinical trials for metastatic pancreatic adenocarcinoma, with potential for interim or final data readouts.
• Progress in Phase 1/2a clinical trials for AGI-134 in solid tumors, which could provide early efficacy and safety data.
• Development and potential commercial launch of BL-5010 under the licensing arrangement with Perrigo Company plc for over-the-counter sale.
• Further results and strategic updates from the collaboration agreements with MSD for cancer immunotherapy and MD Anderson Cancer Center for Motixafortide.

What Are the Key Risks for BLRX?

• Financial-distress signal — its Altman Z-Score of -14.50 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-47.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays for pipeline candidates, including Motixafortide and AGI-134, which could significantly impact the company's valuation and future prospects.
• Significant R&D expenses and a negative profit margin of -633.8%, indicating a continued need for capital raises that could dilute existing shareholders.
• Intense competition within the highly dynamic oncology and biotechnology sectors, which could limit market share for any approved products.
• Regulatory hurdles and challenges in obtaining marketing approval for new drugs from health authorities in various jurisdictions.
• Dependence on strategic collaborations for certain development programs and commercialization efforts, introducing reliance on third-party performance and strategic alignment.

What Are the Growth Opportunities for BLRX?

• Growth opportunity 1: **Commercialization of Motixafortide for Autologous Stem Cell Mobilization.** Motixafortide has successfully completed Phase 3 clinical trials for this indication, representing the most advanced asset in BioLineRx's pipeline. Autologous stem cell mobilization is a critical procedure in various hematologic malignancies, and a new, effective agent could capture a significant share of this established market. The successful completion of Phase 3 trials positions the company for potential regulatory submission and subsequent market entry, which could provide a crucial initial revenue stream. The market for stem cell transplantation support is stable and driven by ongoing cancer treatments, offering a clear commercial pathway for BioLineRx.
• Growth opportunity 2: **Expansion of Motixafortide in Pancreatic Cancer Treatment.** Motixafortide is undergoing Phase 2 clinical trials for metastatic pancreatic adenocarcinoma, building on completed Phase 2a trials for pancreatic cancer. Pancreatic cancer remains one of the most challenging cancers to treat, with a dire prognosis and significant unmet medical need. A successful outcome in these trials, especially in combination with existing therapies like KEYTRUDA through the MD Anderson collaboration, could unlock access to a substantial and high-value oncology market. The potential to improve patient outcomes in this difficult-to-treat cancer represents a major growth driver for the company.
• Growth opportunity 3: **Development of AGI-134 in Immuno-Oncology for Solid Tumors.** AGI-134, an immuno-oncology agent, is currently in Phase 1/2a clinical trials for solid tumors. Immuno-oncology is a rapidly evolving and high-growth segment within cancer therapy, with a global market projected to reach tens of billions of dollars. The mechanism of action for immuno-oncology agents, which harness the body's own immune system to fight cancer, holds immense promise for durable responses across various tumor types. Successful advancement of AGI-134 through clinical development could position BioLineRx to capitalize on this significant market trend and diversify its oncology pipeline beyond Motixafortide.
• Growth opportunity 4: **Commercialization of BL-5010 for Non-Surgical Skin Lesion Removal.** The licensing arrangement with Perrigo Company plc for the over-the-counter (OTC) sale of BL-5010, a proprietary pen-like applicator for non-surgical skin lesion removal, represents a distinct growth opportunity. This product targets a broad consumer market for cosmetic and dermatological solutions, offering a potential near-term revenue stream that is less dependent on the lengthy and high-risk pharmaceutical approval process. The OTC market for dermatological products is substantial, and a convenient, non-surgical option could gain considerable traction, providing BioLineRx with a diversified revenue base and market presence.
• Growth opportunity 5: **Leveraging Strategic Collaborations and Pipeline Diversification.** BioLineRx's collaborations with MSD for cancer immunotherapy and MD Anderson Cancer Center for Motixafortide in pancreatic cancer are critical for de-risking development and expanding potential market reach. These partnerships provide access to significant resources, expertise, and potential co-development or commercialization pathways. Furthermore, the exploration of Motixafortide in acute respiratory distress syndrome (ARDS) secondary to viral infections, solid tumors, and acute myeloid leukemia demonstrates a strategy to diversify the pipeline and explore new therapeutic areas beyond its primary oncology focus, potentially unlocking additional market opportunities and revenue streams in the future.

What Opportunities Does BLRX Have?

• Potential regulatory approval and commercialization of Motixafortide for autologous stem cell mobilization, unlocking a new revenue stream.
• Significant market potential in pancreatic cancer and other solid tumors if Motixafortide and AGI-134 demonstrate efficacy in ongoing trials.
• Expansion into new therapeutic areas like acute respiratory distress syndrome with Motixafortide.
• Leveraging the licensing agreement with Perrigo to establish a presence in the over-the-counter dermatological market with BL-5010.

What Threats Does BLRX Face?

• Risk of clinical trial failures or delays for Motixafortide, AGI-134, or other pipeline candidates.
• Intense competition from larger pharmaceutical companies and other biotechnology firms in oncology.
• Regulatory hurdles and challenges in gaining market approval for new drugs.
• Need for additional capital raises to fund ongoing research and development, potentially leading to shareholder dilution.

What Are BLRX's Competitive Advantages?

• Proprietary clinical-stage pipeline, including advanced assets like Motixafortide with completed Phase 3 trials for a specific indication.
• Strategic collaborations with established pharmaceutical companies (MSD) and leading research institutions (MD Anderson Cancer Center), validating its science and providing access to resources.
• Intellectual property surrounding its drug candidates, such as Motixafortide, AGI-134, and BL-5010, providing exclusivity upon approval.
• Focus on areas of high unmet medical need, particularly challenging cancers like pancreatic cancer, which can lead to significant market opportunities if successful.

What Does BLRX Do?

BioLineRx Ltd., established in 2003 and headquartered in Hevel Modi'in, Israel, is a clinical-stage biopharmaceutical development company primarily dedicated to the oncology sector. The company's strategic focus is on advancing a pipeline of novel therapeutic candidates through various clinical stages. Its flagship product, Motixafortide, a peptide, has successfully completed Phase 3 clinical trials for the critical application of autologous stem cell mobilization, indicating a significant step towards potential market entry. Beyond this, Motixafortide is also being rigorously evaluated for its potential in oncology, having completed Phase 2a clinical trials for pancreatic cancer and currently undergoing Phase 2 clinical trials for metastatic pancreatic adenocarcinoma patients. The company is further exploring Motixafortide's utility in Phase 1b clinical trials for acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for solid tumors and acute myeloid leukemia, showcasing its broad therapeutic potential. In addition to Motixafortide, BioLineRx is developing AGI-134, an immuno-oncology agent, which is progressing through Phase 1/2a clinical trials for the treatment of solid tumors, tapping into a high-growth area of cancer therapy. The pipeline also includes BL-5010, a customized, proprietary, pen-like applicator designed for the non-surgical removal of skin lesions, representing a potential near-term commercial opportunity. BioLineRx strategically enhances its development capabilities through key collaborations, including an agreement with MSD in the cancer immunotherapy field, a partnership with MD Anderson Cancer Center to investigate Motixafortide in combination with KEYTRUDA (pembrolizumab) for pancreatic cancer, and a licensing arrangement with Perrigo Company plc for the over-the-counter sale of BL-5010. These collaborations are crucial for de-risking development and expanding market reach.

What Products and Services Does BLRX Offer?

• Develops Motixafortide, a peptide, for autologous stem cell mobilization, having completed Phase 3 clinical trials.
• Advances Motixafortide through Phase 2 clinical trials for metastatic pancreatic adenocarcinoma and Phase 2a trials for pancreatic cancer.
• Investigates Motixafortide in Phase 1b clinical trials for acute respiratory distress syndrome (ARDS) and other respiratory viral infections.
• Explores Motixafortide's potential for treating solid tumors and acute myeloid leukemia (AML).
• Develops AGI-134, an immuno-oncology agent, currently in Phase 1/2a clinical trials for solid tumors.
• Develops BL-5010, a proprietary pen-like applicator for the non-surgical removal of skin lesions.
• Engages in strategic collaboration with MSD for cancer immunotherapy research and development.
• Partners with MD Anderson Cancer Center to study Motixafortide with KEYTRUDA in pancreatic cancer.
• Has a licensing arrangement with Perrigo Company plc for the over-the-counter sale of BL-5010.

How Does BLRX Make Money?

• Primarily focused on research and development of novel biopharmaceutical products, aiming for regulatory approval and commercialization.
• Seeks to generate revenue through licensing agreements and collaborations for its pipeline assets, such as the arrangement with Perrigo for BL-5010.
• Plans to commercialize approved therapeutic candidates, potentially through direct sales, partnerships, or out-licensing, to generate product sales revenue.
• Leverages strategic partnerships with larger pharmaceutical companies (e.g., MSD) to share development costs, risks, and potentially benefit from milestone payments and royalties.

What Industry Does BLRX Operate In?

BioLineRx Ltd. operates within the highly dynamic and research-intensive biotechnology industry, specifically focusing on the oncology sector. This industry is characterized by significant R&D investments, long development cycles, and high regulatory hurdles, but also by the potential for substantial returns upon successful product commercialization. The global oncology market continues to expand, driven by an aging population, increasing cancer incidence, and advancements in treatment modalities such as immunotherapies and targeted therapies. BioLineRx's pipeline, particularly Motixafortide and AGI-134, positions it within these critical therapeutic areas. The competitive landscape is intense, featuring both large pharmaceutical companies with extensive resources and numerous smaller biotech firms vying for innovative breakthroughs. BioLineRx differentiates itself through its clinical-stage assets and strategic collaborations, aiming to carve out a niche in areas with high unmet medical needs like pancreatic cancer and stem cell mobilization.

Who Are BLRX's Key Customers?

• Healthcare providers and hospitals utilizing autologous stem cell mobilization procedures for cancer patients.
• Oncologists and cancer treatment centers seeking novel therapies for pancreatic cancer, solid tumors, and acute myeloid leukemia.
• Dermatologists and general consumers interested in non-surgical solutions for skin lesion removal (via Perrigo's OTC distribution).
• Pharmaceutical companies seeking collaboration opportunities for drug development and commercialization.

Company Profile

BioLineRx Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hevel Modi'in, IL. The company is led by CEO Philip A. Serlin. BLRX has traded publicly since 2011.

BioLineRx Ltd. Financial Trajectory

BioLineRx Ltd. (BLRX) reported $477K in revenue for Q1 2026, reflecting 144.4% growth compared to the prior quarter. The company recorded a net loss of $2.6M, with diluted EPS of $-0.58. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BLRX averaged $-0.53 in diluted EPS.

How BioLineRx Ltd. Is Valued

BioLineRx Ltd. carries a market capitalization of $14.01M, placing it in the micro-cap category. Relative to its peer group, BLRX's quantitative score of 69/100 is roughly in line with the peer average of 76/100.

ROE -48%Key Financial Metrics

Return on equity for BioLineRx Ltd. stands at -47.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -23.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -56.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.58 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -62.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

BioLineRx Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.50 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project BioLineRx Ltd. revenue of about $1.8M for fiscal 2026, with EPS near $-0.47.

BLRX Financials

BLRX Latest News

BLRX Analyst Consensus

BLRX MoonshotScore

Common Questions About BLRX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources